Researchers found that people with Parkinson's disease have lower levels of GM1 ganglioside (a fatty molecule) in their brain, nervous system, and skin. This deficiency showed up not just in brain tissue but also in skin cells and immune cells, suggesting it's a widespread problem in PD—not just a brain issue. Mouse studies supported this finding and suggested that replacing GM1 could potentially help treat the disease.

This was a review study that analyzed findings across multiple tissue types (brain, skin, heart, colon, immune cells) in Parkinson's patients and tested the theory using a mouse model with reduced GM1 levels.

Funding not disclosed in abstract